Surgery and Tile-Based Radiation Therapy Versus Surgery and Stereotactic Radiation for Newly Diagnosed Brain Metastases: A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology · 10.11.2026
DOI: 10.1200/jco-26-01894 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 10.11.2026. Verfasst von Jeffrey S Weinberg und 49 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, TX. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Purpose
Postoperative stereotactic radiation (SRT) is the standard-of-care for resected brain metastases. Implantation of cesium-131 collagen tiles (tile-based radiation therapy [TBRT]) initiates focal radiation immediately after resection, potentially offering therapeutic and logistical advantages. Radiation One and Done Study, a randomized, open-label, noninferiority, phase III trial (ClinicalTrials.gov identifier: NCT04365374 ), compared the safety and efficacy of resection with TBRT (R + TBRT) with resection with SRT (R + SRT) for patients with a newly diagnosed brain metastasis indicated for surgical resection.
Methods
Across 32 US centers, patients were preoperatively randomly assigned 1:1 to R + TBRT or R + SRT. Any nonresected brain metastases received SRT postoperatively. Co-primary outcomes were time-to-surgical bed recurrence (SBR) and surgical bed recurrence-free survival (SB-RFS). Outcomes were analyzed using Cox proportional hazards models with stratification factors as covariates. Multiplicity was controlled by hierarchical testing. Analyses used the prespecified modified intention-to-treat (mITT) population (patients who underwent surgery, had pathologic confirmation of brain metastasis, and had follow-up information).
Results
From April 2021 to August 2025, 230 patients were randomly assigned (115 per arm), 204 of whom (103 R + TBRT, 101 R + SRT) comprised the mITT population. The median follow-up was 12.9 months. The median time-to-SBR was not reached in R + TBRT versus 17.4 months in R + SRT (hazard ratio [HR]: 0.06 [95% CI, 0.01 to 0.46]; P = .0070). SB-RFS was improved with R + TBRT, with a median of not reached versus 10.9 months in R + SRT (HR, 0.48 [95% CI, 0.30 to 0.76]; P = .0021). Overall adverse events did not appear to differ: 83 patients (79.0% [95% CI, 70.0 to 86.4]) in R + TBRT versus 67 patients (80.7% [95% CI, 70.6 to 88.6]) in R + SRT.
Conclusion
For patients with newly diagnosed brain metastases requiring resection, R + TBRT significantly improved SBR and SB-RFS, demonstrating both noninferiority and superiority.
Autor:innen und Institutionen
- The University of Texas MD Anderson Cancer Center, Houston, TX.
- Memorial Sloan Kettering Cancer Center, New York, NY.
- Mayfield Brain & Spine, Cincinnati, OH.
- Emory University School of Medicine, Atlanta, GA.
- University of Kansas, Lawrence, KS.
- AdventHealth Orlando, Orlando, FL.
ORCID-Profile: Jeffrey S Weinberg, Brandon S Imber, Nelson S Moss, Akshitkumar M Mistry, Michael A Garcia, Hussein Tawbi, Robert Ryan, Lindsey Sloan, Ken Tatebe, Colette J Shen, Angela M Richardson, Gregory B Biedermann, Aristotelis Filippidis, Heather Lin, Akash J Patel, M Sean Peach, Frederick F Lang, Rajat J Kudchadker, Jeffrey Wefel, Ying Yuan, Simon Hanft, Thomas H Beckham
Zitieren
APA
Weinberg, J. S., Imber, B. S., DiNapoli, V., Moss, N. S., Hoang, K. B., Wang, F., Mohiuddin, I., Mistry, A. M., Garcia, M. A., Tawbi, H., Patel, N. V., Pham, H., Ryan, R., Wanebo, J., Smith, K., Chen, C. C., Paul, A., Sloan, L., Shepard, M. J., …, & Beckham, T. H. (2026). Surgery and Tile-Based Radiation Therapy Versus Surgery and Stereotactic Radiation for Newly Diagnosed Brain Metastases: A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01894
Vancouver
Weinberg JS, Imber BS, DiNapoli V, Moss NS, Hoang KB, Wang F, et al. Surgery and Tile-Based Radiation Therapy Versus Surgery and Stereotactic Radiation for Newly Diagnosed Brain Metastases: A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-01894
BibTeX
@article{Weinberg2026,
author = {Weinberg, Jeffrey S and Imber, Brandon S and DiNapoli, Vincent and Moss, Nelson S and Hoang, Kimberly B and Wang, Fen and Mohiuddin, Imran and Mistry, Akshitkumar M and Garcia, Michael A and Tawbi, Hussein and Patel, Nitesh V and Pham, Huong and Ryan, Robert and Wanebo, John and Smith, Kris and Chen, Clark C and Paul, Alexandra and Sloan, Lindsey and Shepard, Matthew J and Tatebe, Ken and Shen, Colette J and Brachman, David G and Richardson, Angela M and Evans, Linton T and Biedermann, Gregory B and Robin, Adam and Patel, Toral R and Filippidis, Aristotelis and Lin, Heather and Chambless, Lola B and Dombrowski, John and Patel, Akash J and Chowdhary, Sajeel and Lee, K Stuart and Peach, M Sean and Nowlan, Adam and McCracken, David J and Floyd, John and Xia, Fen and Rudnick, Jeremy and Li, Jing and Yeboa, Debra Nana and Lang, Frederick F and Kudchadker, Rajat J and McAleer, Mary Frances and Wefel, Jeffrey and Ferguson, Sherise Desiree and Yuan, Ying and Hanft, Simon and Beckham, Thomas H},
title = {Surgery and Tile-Based Radiation Therapy Versus Surgery and Stereotactic Radiation for Newly Diagnosed Brain Metastases: A Randomized, Open-Label, Phase III Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-01894}
}
EUVIMED